Publications by authors named "Shang-Ju Wu"
Background: Atrial fibrillation (AF) increases the risks of stroke and mortality. It remains unclear whether rhythm control reduces the risk of stroke in patients with AF concomitant with hypertrophic cardiomyopathy (HCM).
Methods: We identified AF patients with HCM who were ≥ 18 years old in the Taiwan National Health Insurance Database.
Monoclonal antibodies enhance innate immunity, while bispecific T cell engager antibodies redirect adaptive T cell immunity. To stimulate both innate and adaptive mechanisms, we created a bifunctional eCD16A/anti-CD3-BFP adapter protein for combined use with clinically approved monoclonal IgG1 antibodies. The adaptor protein contains the extracellular domain of the human CD16A high-affinity variant, which binds the Fc domain of IgG1 antibodies, and an anti-human CD3 single-chain variable fragment that redirects T cell cytotoxicity.
View Article and Find Full Text PDFPeople living with HIV (PLWH) have an increased risk of developing cancers, especially hematologic malignancies (HM). Hematopoietic stem cell transplantation (HSCT) has been an important treatment modality for patients with HM. However, the experience of HSCT in PLWH with HM remains limited in Asia.
View Article and Find Full Text PDFBackground: Acute kidney injury (AKI) is a serious complication following high-dose methotrexate (HD-MTX) treatment, despite established preventive measures. This study presents a case report and a retrospective review of patients treated with HD-MTX, aiming to identify risk factors for AKI and propose a modified treatment protocol.
Methods: We report a case of a 43-year-old man with diffuse large B-cell lymphoma who developed severe AKI after HD-MTX therapy.
Article Synopsis
- - The study investigated the relationship between the distance from the descending aorta to the left inferior pulmonary vein (Dao-LIPV) and the presence of triggers and drivers in atrial fibrillation (AF) during ablation procedures.
- - A total of 886 patients with drug-refractory AF were analyzed; 63 were found to have LIPV triggers or drivers, with Dao-LIPV distance proving to be a strong predictor for these occurrences.
- - The research developed a risk score model indicating that patients with a Dao-LIPV distance of 2.5 mm or less and persistent AF have a significantly higher risk of LIPV triggers or drivers, which can help electrophysiologists plan ablation treatments more effectively.*
Flow cytometry can be applied in the detection of fluorescence in situ hybridisation (FISH) signals to efficiently analyse chromosomal aberrations. However, such interphase chromosome (IC) Flow-FISH protocols are currently limited to detecting a single colour. Furthermore, combining IC Flow-FISH with conventional multicolour flow cytometry is difficult because the DNA-denaturation step in FISH assay also disrupts cellular integrity and protein structures, precluding subsequent antigen-antibody binding and hindering concurrent labeling of surface antigens and FISH signals.
View Article and Find Full Text PDFArticle Synopsis
- Signal-averaged electrocardiography (SAECG) was studied in patients with nonischemic cardiomyopathies (NICMs) to determine its diagnostic and prognostic value regarding ventricular arrhythmia (VA).
- In a study of 58 NICM patients, those who met at least one SAECG criterion showed larger areas of scar tissue and more frequently had extremely low-voltage zones than those who did not meet the criteria.
- The findings suggest that a positive SAECG indicates a greater risk for arrhythmogenic issues in NICM patients, although it did not significantly correlate with long-term recurrence of ventricular arrhythmias.
Background: The prognosis for people living with HIV (PLWH) who develop lymphomas has been greatly improved by combination antiretroviral therapy (cART) and anti-CD20 monoclonal antibodies. However, real-world clinical data on this patient group in Asia are limited.
Methods: Treatment outcomes were retrospectively examined for 104 PLWH with lymphomas between 2000 and 2019.
Background: Patients with hematological malignancies (HM) were at a high risk of developing severe disease from coronavirus disease 2019 (COVID-19). We aimed to assess the clinical outcome of COVID-19 in hospitalized patients with HM.
Methods: Adult patients with HM who were hospitalized with a laboratory-confirmed COVID-19 between May, 2021 and November, 2022 were retrospectively identified.
Article Synopsis
- Glofitamab, a bispecific antibody, shows promise for treating relapsed/refractory B-cell lymphoma based on a phase 1/2 clinical trial, and this study aimed to evaluate its effectiveness in a real-world setting.
- The multicenter retrospective study included 34 patients with advanced lymphoma who received glofitamab treatment in Taiwan, revealing a 56% overall response rate and a 23% complete remission rate at a median follow-up of 15.9 months.
- Results indicated that previous treatment effectiveness correlated with glofitamab response, with manageable cytokine release syndrome reported, and no instances of hepatitis B virus reactivation in the studied patients.
Introduction: Catheter ablation is an effective and safe strategy for treating atrial fibrillation patients. Nevertheless, studies on the long-term outcomes of catheter ablation in patients with dilated cardiomyopathy are limited. This study aimed to assess the electrophysiological characteristics of atrial fibrillation patients with dilated cardiomyopathy and compare the long-term clinical outcomes between patients undergoing catheter ablation and medical therapy.
View Article and Find Full Text PDFBackground: Diffuse large B-cell lymphoma (DLBCL) of the head-and-neck area primarily involves the Waldeyer ring (WR) and sinonasal area (SN). However, the differential clinical outcomes between patients with WR-DLBCL and those with SN-DLBCL in the rituximab era remain unclear.
Methods: To avoid confounding factors contributed by advanced DLBCL with WR and SN involvement, we assessed the clinical outcomes of patients with stage I/II WR-DLBCL and SN-DLBCL and compared them with those having corresponding stages of DLBCL in the lymph nodes but without other extranodal involvement (LN-DLBCL) in the same period.
Article Synopsis
- The study examines how catheter ablation (CA) of atrial fibrillation (AF) affects the severity of mitral regurgitation (MR) in patients who have both conditions, analyzing data from 2011 to 2021.
- Of the 50 patients analyzed, those with improved MR after CA (group 1) had fewer risk factors like hypertension and diabetes, and less scar tissue in the left atrium compared to those with refractory MR (group 2).
- The results indicate that while most patients experience improved MR post-ablation, the presence of scar tissue in the posterior bottom of the left atrium predicts a poorer outcome in terms of MR recovery.
Article Synopsis
- This study compares the effectiveness of circumferential pulmonary vein isolation (CPVI) and segmental pulmonary vein isolation (SPVI) in patients undergoing redo ablations for recurrent atrial fibrillation (AF).
- 543 patients who had AF ablation were analyzed, with 141 included in the final assessment; the results showed similar AF-free survival rates for both techniques, but a significant difference in atrial flutter recurrence favoring CPVI.
- The findings suggest that while SPVI and CPVI are comparable for AF recurrence, SPVI has a higher rate of atrial flutter, potentially linked to more residual pulmonary vein gaps over time.
Targeted therapy with Bruton tyrosine kinase (BTK) inhibitors have revolutionized the treatment of patients with various B-cell malignancies. BTK inhibitors such as ibrutinib, zanubrutinib, orelabrutinib, and acalabrutinib have shown good clinical efficacy and better safety profiles than those of traditional chemotherapy and chemoimmunotherapy regimens. Multiple studies on new BTK inhibitors are ongoing, which may provide more therapeutic options for the treatment of B-cell malignancies.
View Article and Find Full Text PDFPrevious studies have explored the use of engineered blinatumomab-secreting autologous αβ T cells for CD19-targeted cancer therapy. To create a more flexible allogeneic delivery system, we utilized γ9δ2 T cells rather than αβ T cells in a similar application. First, we showed that γ9δ2 T cells could serve as effector cells for blinatumomab, and these effector memory cells could survive for at least 7 days after infusion.
View Article and Find Full Text PDFBackground: Therapeutic hypothermia (TH) increases the susceptibility to ventricular arrhythmias (VAs) by prolonging action potential duration (APD) and facilitating arrhythmogenic spatially discordant alternans (SDA). Levosimendan, a calcium sensitizer, has been reported to shorten APD by enhancing the adenosine triphosphate (ATP)-sensitive K current.
Objective: The purpose of this study was to test the hypothesis that, during TH, levosimendan shortens the already prolonged APD, attenuates SDA, and prevents VA.
The mass and concentration of hemoglobin per erythrocyte are important hematological parameters. Measuring these parameters from intact erythrocytes requires the value of specific refraction-index increment (RII) of oxygenated hemoglobin, which diverges in the literature. Refractive indices of hemoglobin solutions are measured directly by digital holographic microscopy on a microfluidic channel filled with hemoglobin solutions prepared by hemolysis of fresh human erythrocytes and refractive-index standards sequentially.
View Article and Find Full Text PDFArticle Synopsis
- Glofitamab, a bispecific antibody, shows promise for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL), with 39% of patients achieving a complete response after treatment.
- In a phase 2 trial involving patients who had undergone at least two previous therapies, the medication was administered following obinutuzumab pretreatment to reduce side effects.
- Although the treatment was effective, 78% of complete responses were ongoing at 12 months, but 62% of patients experienced significant adverse events, primarily cytokine release syndrome.
The increased expression of programmed death-ligands 1 and 2 (PD-L1 and PD-L2, respectively) on tumour cells contributes to immune evasion, suggesting that these proteins are attractive therapeutic targets. This study aimed to evaluate the validity of cerebrospinal fluid (CSF) soluble PD-L1 (sPD-L1) and soluble PD-L2 (sPD-L2) as biomarkers for primary central nervous system lymphoma (PCNSL). We determined the CSF concentrations of sPD-L1 and sPD-L2 in 46 patients with PCNSL using enzyme-linked immunosorbent assays (ELISAs).
View Article and Find Full Text PDFArticle Synopsis
- * A multicenter study in Taiwan analyzed the gene rearrangements of 255 CLL patients, identifying IGHV3-7, IGHV4-34, and IGHV3-23 as the most commonly rearranged genes.
- * The study found that major subsets of B-cell receptor stereotypy were less common in Asian patients, with subsets #77 and #28A being the most prevalent, indicating unique immunogenetic traits in CLL for Asian populations.